The FDA approval and initial commercial availability of CRISPR-based gene therapy for sickle cell disease and beta thalassemia has marked the beginning of a new era in genetic medicine. Early treated patients are reporting dramatic reductions in painful crises and transfusion dependence that previous treatments could not achieve. The durability of the therapeutic effect, now observed at three-year follow-up in the earliest treated patients, appears to be maintained.
The treatments currently approved are one-time procedures costing approximately 2 to 3 million dollars per patient, raising profound healthcare access and equity questions as breakthrough genetic therapies are technically available but financially inaccessible to patients without exceptional insurance coverage or personal resources. Manufacturers, payers, and policymakers are developing outcome-based payment models that might spread costs over the treatment lifetime, but no consensus framework has yet emerged.
